Skip to main content
OpenTrials

Clinical trial condition

Chronic Lymphoid Leukemia

Explore clinical trials studying Chronic Lymphoid Leukemia. Study availability and eligibility vary by location and protocol.

9 public trials 1 recruiting study
Refine in advanced search Browse all conditions

Chronic Lymphoid Leukemia trial results

Recruiting

Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning

NCT03852407

Conditions
Acute Lymphoid Leukemia in Remission, Acute Myeloid Leukemia in Remission, Blood Protein Disorders, +33 more
Locations
  • ZNA Stuivenberg Antwerp, Belgium
  • AZ Sint Jan Brugge Bruges, Belgium
  • IJ Bordet Brussels, Belgium
  • UZ Brussel Brussels, Belgium
View Trial Details
Completed

Efficacy of Acalabrutinib in Very Old or Frail Patients With Treatment-naïve or Relapsed/Refractory CLL

NCT04883749

Conditions
Chronic Lymphoid Leukemia, Hematologic Diseases, Hemic and Lymphatic Diseases, +9 more
Locations
  • Medizinische Universität Innsbruck Innsbruck, Austria
  • Hanusch Krankenhaus Vienna, Austria
  • Onkologische Schwerpunktpraxis Kurfürstendamm Berlin, Germany
  • Universitätsklinik Köln Cologne, Germany
View all 20 locations
View Trial Details
Completed

Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers

NCT00788684

Conditions
CD20-Positive Lymphoid Malignancies, Chronic Lymphoid Leukemia, Hematologic Diseases, +16 more
Locations
  • University of Arizona Cancer Center - North Campus /ID# 16721 Tucson, Arizona, United States
  • Stanford University School of Med /ID# 9782 Stanford, California, United States
  • Cleveland Clinic Main Campus /ID# 9784 Cleveland, Ohio, United States
  • Univ of Wisconsin Hosp/Clinics /ID# 21701 Madison, Wisconsin, United States
View Trial Details
Completed

Sequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients With Relapsed/Refractory CLL

NCT03787264

Conditions
Chronic Lymphoid Leukemia, Hematologic Diseases, Hemic and Lymphatic Diseases, +9 more
Locations
  • Universitätsklinik Köln Cologne, Germany
  • Gemeinschaftspraxis Hämatologie Onkologie Dresden, Germany
  • Gemeinschaftspraxis Mohm/Prange-Krex Dresden, Germany
  • Universitatsklinik Carl Gustav Carus Dresden, Germany
View all 17 locations
View Trial Details
Completed

A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies

NCT00406809

Conditions
Chronic Lymphoid Leukemia, Follicular Lymphoma, Hematologic Diseases, +25 more
Locations
  • Site Reference ID/Investigator# 4997 Los Angeles, California, United States
  • Site Reference ID/Investigator# 9104 Los Angeles, California, United States
  • Site Reference ID/Investigator# 2613 Bethesda, Maryland, United States
  • Site Reference ID/Investigator# 40243 Boston, Massachusetts, United States
View Trial Details
Active, Not Recruiting

Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)

NCT04608318

Conditions
Chronic Lymphoid Leukemia, Hematologic Diseases, Hemic and Lymphatic Diseases, +9 more
Locations
  • LKH-Universtitätsklinikum Graz Graz, Austria
  • Landeskrankenhaus - Universitätskliniken Innsbruck Innsbruck, Austria
  • Medizinische Universität Wien Vienna, Austria
  • Hanusch Krankenhaus Vienna, Austria
View all 181 locations
View Trial Details
Active, Not Recruiting

Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL

NCT04515238

Conditions
Chronic Lymphoid Leukemia, Hematologic Diseases, Hemic and Lymphatic Diseases, +9 more
Locations
  • Hamatologische/Onkologische Gemeinschaftspraxis Augsburg, Germany
  • Universitätsklinik Köln Cologne, Germany
  • Onkologische Schwerpunktpraxis Esslingen am Neckar, Germany
  • Evangelische Krankenhaus Hamm Hamm, Germany
View Trial Details

Related conditions